PRT12396

About Prelude Therapeutics

Prelude Therapeutics is a publicly traded, clinical-stage biotech focused on discovering and developing targeted cancer therapies. The company has built a diverse pipeline of 11 candidates, with key programs including a selective SMARCA2 degrader (PRT3789) for SMARCA4-mutant cancers and a CDK9 inhibitor (PRT2527) for hematologic and solid tumors. Its strategy centers on applying novel mechanisms like targeted protein degradation to clinically validated targets to create differentiated, precision medicines. Prelude operates with an integrated R&D team aiming to translate scientific insights into transformative treatments for patients.

Therapeutic Areas